Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,341 result(s) found. Displaying page 1,778 of 2,218.
    «« First « Previous 1774  1775  1776  1777  1778  1779  1780  1781  1782  Next» Last»»
    EudraCT Number: 2022-002485-32 Sponsor Protocol Number: CTRIAL-IE-22-01 Start Date*: 2023-03-07
    Sponsor Name:Cancer Trials Ireland
    Full Title: Single arm phase 2 trial of neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a standard chemotherapy-sparing approach...
    Medical condition: HER2-positive breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-003188-24 Sponsor Protocol Number: CA184-587 Start Date*: 2020-11-13
    Sponsor Name:Sahlgrenska University Hospital
    Full Title: A Phase I Randomized Controlled Multicentre Trial of Isolated Hepatic Perfusion in Combination with Ipilimumab and Nivolumab in Patients with Uveal Melanoma Metastases
    Medical condition: Metastatic uveal melanoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10081431 Uveal melanoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000375-25 Sponsor Protocol Number: BotA-KKDS2016 Start Date*: 2016-04-19
    Sponsor Name:Danderyds sjukhus AB
    Full Title: Double blind placebo-controlled RCT of the efficacy and safety of intramuscular injections of Botulinum Toxin A as a treatment for provoked vestibulodynia
    Medical condition: Provoked vestibulodynia
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-019635-36 Sponsor Protocol Number: 2010-001 Start Date*: 2010-05-04
    Sponsor Name:Aker BioMarine Antarctic AS
    Full Title: A Single Centre, Open-Label, Randomised Multi-Dose Study to Assess Changes in the Brain Metabolism of Juvenile ADHD Patients After Thirteen Weeks of Daily Intake of 4 g Superba Krill Oil or 4 g ome...
    Medical condition: Attention deficit/hyperactivity disorder
    Disease: Version SOC Term Classification Code Term Level
    12.1 10003736 Attention deficit/hyperactivity disorder LLT
    Population Age: Children, Under 18 Gender: Male
    Trial protocol: IS (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-016094-16 Sponsor Protocol Number: AGO/2009/008 Start Date*: 2010-02-04
    Sponsor Name:University Hospital Ghent
    Full Title: Sevoflurane-Remifentanil interaction: Multiple response surfaces, validation of calibration stimuli, validation of the intraoperative isobole concept and investigating remifentanil induced opioid t...
    Medical condition: American Society of Anesthesia class I and II patients scheduled for surgery under general anesthesia.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10002323 Anesthesia general LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2008-008202-52 Sponsor Protocol Number: REMARC Start Date*: 2009-09-14
    Sponsor Name:LYSARC
    Full Title: DOUBLE BLIND RANDOMIZED PHASE III STUDY OF LENALIDOMIDE (REVLIMID®) MAINTENANCE VERSUS PLACEBO IN RESPONDING ELDERLY PATIENTS WITH DLBCL AND TREATED WITH R-CHOP IN FIRST LINE
    Medical condition: Diffuse Large B Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) PT (Completed) ES (Completed) AT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-003889-39 Sponsor Protocol Number: NALPAC Start Date*: 2021-10-11
    Sponsor Name:Belgian Group of Digestive Oncology (BGDO)
    Full Title: A Non-Comparative Randomized Phase 2 Study, Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for Metastatic Pancreatic Ductal Adenocarcinoma (PDAC), Progressive After Gemcitabine-Abra...
    Medical condition: Pancreatic ductal adenocarcinoma (PDAC)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-004142-11 Sponsor Protocol Number: A011-11 Start Date*: 2021-05-12
    Sponsor Name:Acceleron Pharma Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Sotatercept Versus Placebo When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy...
    Medical condition: Pulmonary Arterial Hypertension (PAH)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) FR (Completed) BE (Completed) NL (Completed) AT (Completed) PL (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000971-26 Sponsor Protocol Number: RHF-CAELYX-002 Start Date*: 2016-04-04
    Sponsor Name:Charles University in Prague, Medical Faculty
    Full Title: Liposoms (drug delivery systems) in kinetically guided therapy of ovarian platinum-resistant carcinoma with doxorubicin using plasmafiltration
    Medical condition: Chemotherapy of ovarian platinum-resistant carcinoma
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-001512-65 Sponsor Protocol Number: MEMMATCZ Start Date*: 2012-06-19
    Sponsor Name:Masaryk University
    Full Title: A Phase II study of metronomic and targeted anti-angiogenesis therapy for children with recurrent/progressive medulloblastoma
    Medical condition: recurrent or progressive medulloblastoma
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001419-25 Sponsor Protocol Number: GastricCHIMERAtrial Start Date*: 2021-04-09
    Sponsor Name:Jagiellonian University Medical College
    Full Title: Preoperative intraperitoneal chemotherapy in adjuvant hyperthermia adjunctive therapy in advanced gastric cancer with high-risk of peritoneal recurrence - a multicentre randomized trial
    Medical condition: Gastric Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007350 Carcinoma gastric LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-003574-16 Sponsor Protocol Number: MK3475-059 Start Date*: 2015-05-08
    Sponsor Name:Merck Sharp & Dohme Corp., a Subsidiary of Merck & Co., Inc.
    Full Title: A Phase II Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin+5-Fluorouracil in Subjects with Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcino...
    Medical condition: Gastric Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) LT (Completed) EE (Completed) FR (Completed) RO (Temporarily Halted) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-002125-19 Sponsor Protocol Number: 9494 Start Date*: 2016-06-20
    Sponsor Name:CHU MontpellierCentre administratif André Benech,
    Full Title: A phase IIb, prospective, multicentre, double-blind, triple-arm, randomized versus placebo trial, to assess the efficacy of a single injection of either 2 or 10 x 106 autologous adipose derived mes...
    Medical condition: Active knee Osteoarthritis (mild to moderate)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) NL (Completed) DE (Completed) IE (Completed) GB (GB - no longer in EU/EEA) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-002746-40 Sponsor Protocol Number: VX22-864-108 Start Date*: 2023-04-11
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 2, Open-label Study Evaluating Efficacy and Safety of VX-864 in Subjects With Alpha-1 Antitrypsin Deficiency Who Have the PiZZ Genotype, Over 48 Weeks
    Medical condition: Alpha 1 antitrypsin deficiency in Subjects With the PiZZ Genotype
    Disease: Version SOC Term Classification Code Term Level
    23.1 10010331 - Congenital, familial and genetic disorders 10083869 Alpha-1 antitrypsin deficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-001916-44 Sponsor Protocol Number: MiFlaPRO_2019 Start Date*: 2020-01-28
    Sponsor Name:Medical University Innsbruck, Department of Visceral, Transplant und Thoracic Surgery
    Full Title: A multicenter, randomized, double blind placebo controlled trial of Micronized purified Flavonoid- Fraction (MPFF) in the management of radiation proctitis
    Medical condition: Patients with radiation proctitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-001072-11 Sponsor Protocol Number: CO41012 Start Date*: 2019-08-21
    Sponsor Name:Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
    Full Title: A PHASE IB/III STUDY OF IPATASERTIB PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN HORMONE RECEPTOR POSITIVE AND HER2 NEGATIVE LOCALLY ADVANCED UNRESECTABLE OR ...
    Medical condition: Hormone receptor (HR)-positive/HER2-negative locally advanced unresectable or metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    20.0 100000004864 10072740 Locally advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-000081-15 Sponsor Protocol Number: M19-051 Start Date*: 2021-08-24
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose- Ranging Study to Evaluate the Safety and Efficacy of Upadacitinib in Subjects with Non-Segmental Vitiligo
    Medical condition: Vitiligo
    Disease: Version SOC Term Classification Code Term Level
    21.1 10040785 - Skin and subcutaneous tissue disorders 10047642 Vitiligo PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2020-004391-18 Sponsor Protocol Number: PI2020_843_0114 Start Date*: 2020-10-28
    Sponsor Name:CHU Amiens-Picardie
    Full Title: IMPACT OF ANTI-TNF, VEDOLIZUMAB AND TOFACITINIB ON AORTIC STIFFNESS, CAROTID INTIMA-MEDIA THICKNESS AND CARDIOVASCULAR RISK OF PATIENTS WITH ULCERATIVE COLITIS
    Medical condition: ulcerative colitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-001015-23 Sponsor Protocol Number: APHP180668 Start Date*: 2020-05-13
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Double blind, multicentric, randomized, placebo-controlled trial, evaluating the efficacy of 24-month of bezafibrate in primary sclerosing cholangitis with persistent cholestasis despite ursodeoxyc...
    Medical condition: Adult patients with primary sclerosing cholangitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-000254-28 Sponsor Protocol Number: RC31/19/0500 Start Date*: 2022-05-19
    Sponsor Name:University Hospital of Toulouse
    Full Title: Interest of oxytocin as an adjuvant treatment of psycho-educational measures in challenging behaviors in children with autism spectrum disorders and moderate to severe intellectual disability: feas...
    Medical condition: autism
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10003805 Autism LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 1774  1775  1776  1777  1778  1779  1780  1781  1782  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jun 03 19:13:34 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA